67080N119
Nuvation Bio Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that develops targeted drugs for hard-to-treat cancers, Nuvation Bio makes the oral lung-cancer medicine IBTROZI (taletrectinib), approved by U.S. regulators in 2025 for patients whose non-small cell lung cancer carries a specific ROS1 gene change. It was founded in 2018 by Dr. David Hung, the same doctor behind the prostate-cancer drugmaker Medivation. The name blends "Nu-" with "-vation," a nod to innovation and to Hung's earlier Medivation success.
WARRANTUnderlying: NUVBCUSIP: 67080N119HealthcareUS
*W EXP 07/07/202
No recent activity for this security.